As global markets grapple with various challenges, including concerns over artificial intelligence valuations and economic uncertainties, investors are increasingly exploring diverse opportunities. Penny stocks, a term that may seem outdated but remains relevant, refer to smaller or newer companies that can offer affordability and growth potential. By focusing on those with strong financials and clear growth paths, investors might discover promising prospects in the Asian market.
Top 10 Penny Stocks In Asia
| Name | Share Price | Market Cap | Rewards & Risks |
| JBM (Healthcare) (SEHK:2161) | HK$2.85 | HK$2.32B | ✅ 3 ⚠️ 1 View Analysis > |
| Lever Style (SEHK:1346) | HK$1.54 | HK$952.52M | ✅ 4 ⚠️ 1 View Analysis > |
| TK Group (Holdings) (SEHK:2283) | HK$2.54 | HK$2.11B | ✅ 4 ⚠️ 1 View Analysis > |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD1.09 | SGD441.77M | ✅ 4 ⚠️ 2 View Analysis > |
| T.A.C. Consumer (SET:TACC) | THB4.90 | THB2.94B | ✅ 3 ⚠️ 3 View Analysis > |
| Atlantic Navigation Holdings (Singapore) (Catalist:5UL) | SGD0.102 | SGD53.4M | ✅ 2 ⚠️ 4 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD3.40 | SGD13.38B | ✅ 5 ⚠️ 1 View Analysis > |
| Anton Oilfield Services Group (SEHK:3337) | HK$1.06 | HK$2.85B | ✅ 4 ⚠️ 1 View Analysis > |
| Livestock Improvement (NZSE:LIC) | NZ$1.07 | NZ$152.31M | ✅ 2 ⚠️ 5 View Analysis > |
| Rojana Industrial Park (SET:ROJNA) | THB4.36 | THB8.81B | ✅ 3 ⚠️ 3 View Analysis > |
Click here to see the full list of 942 stocks from our Asian Penny Stocks screener.
We're going to check out a few of the best picks from our screener tool.
Guoquan Food (Shanghai) (SEHK:2517)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Guoquan Food (Shanghai) Co., Ltd. operates as a home meal products company in Mainland China, with a market cap of HK$11.32 billion.
Operations: The company generates revenue primarily from its retail grocery stores segment, amounting to CN¥7.04 billion.
Market Cap: HK$11.32B
Guoquan Food (Shanghai) Co., Ltd. is trading at a significant discount to its estimated fair value, suggesting potential undervaluation. The company has shown robust earnings growth of 50.5% over the past year, outpacing the industry average and demonstrating high-quality earnings. Its financial health is strong with cash exceeding total debt and sufficient coverage of short- and long-term liabilities by assets. However, the board's inexperience could be a concern for governance stability. Recent share repurchase initiatives aim to enhance shareholder value by increasing net asset value per share, indicating proactive capital management strategies amidst stable volatility levels.
- Jump into the full analysis health report here for a deeper understanding of Guoquan Food (Shanghai).
- Examine Guoquan Food (Shanghai)'s earnings growth report to understand how analysts expect it to perform.
China Overseas Grand Oceans Group (SEHK:81)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: China Overseas Grand Oceans Group Limited is an investment holding company that focuses on investing in, developing, and leasing real estate properties in the People’s Republic of China and Hong Kong, with a market cap of HK$8.68 billion.
Operations: The company generates revenue primarily from property development, amounting to CN¥38.08 billion, and commercial property operations, contributing CN¥508.16 million.
Market Cap: HK$8.68B
China Overseas Grand Oceans Group Limited, with a market cap of HK$8.68 billion, faces challenges in the real estate sector as evidenced by declining contracted sales and gross floor area year-on-year. The company’s financial health shows mixed signals; while short-term assets cover both short- and long-term liabilities, operating cash flow does not adequately cover debt. A significant one-off loss has impacted recent earnings, and profit margins have decreased to 0.9% from last year's 2.9%. Despite these hurdles, the management team is experienced with stable tenure, though dividend sustainability remains uncertain amid an unstable track record.
- Get an in-depth perspective on China Overseas Grand Oceans Group's performance by reading our balance sheet health report here.
- Evaluate China Overseas Grand Oceans Group's prospects by accessing our earnings growth report.
Hunan Er-Kang Pharmaceutical (SZSE:300267)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Hunan Er-Kang Pharmaceutical Co., Ltd is engaged in the manufacturing and sale of APIs, finished drug products, and pharmaceutical excipients both in China and internationally, with a market cap of CN¥8.00 billion.
Operations: Hunan Er-Kang Pharmaceutical Co., Ltd has not reported specific revenue segments.
Market Cap: CN¥8B
Hunan Er-Kang Pharmaceutical Co., Ltd, with a market cap of CN¥8 billion, shows signs of financial stability despite past profitability challenges. Recent earnings for the nine months ended September 2025 indicate a turnaround, with net income reaching CN¥39.58 million compared to a loss the previous year. The company’s debt is well-covered by operating cash flow at 62.5%, and it holds more cash than its total debt. Short-term assets significantly exceed liabilities, suggesting strong liquidity management. However, the company's return on equity remains negative due to ongoing unprofitability issues over recent years.
- Click to explore a detailed breakdown of our findings in Hunan Er-Kang Pharmaceutical's financial health report.
- Explore historical data to track Hunan Er-Kang Pharmaceutical's performance over time in our past results report.
Next Steps
- Click through to start exploring the rest of the 939 Asian Penny Stocks now.
- Interested In Other Possibilities? Uncover 13 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Hunan Er-Kang Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com